November 13, 2008 - Medtronic Inc. said yesterday its enrollment in the 2,300-patient RESOLUTE All-Comers (R-AC) ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
November 12, 2008
November 13, 2008 - Based on its recent analysis of the drug eluting-stents (DES) market, Frost & Sullivan today ...
November 12, 2008November 11, 2008 - Global Therapeutics today initiated of the world's first clinical trial of a drug-eluting stent that ...
November 10, 2008Boston Scientific's TAXUS Express2 Atom paclitaxel-eluting coronary stent system is a drug-eluting stent (DES) ...
October 30, 2008October 31, 2008 - Surface modification and drug delivery technologies company SurModics Inc. said today it is providing ...
October 30, 2008October 30, 2008 - Medtronic Inc. said today it plans to launch its portfolio of angioplasty products in the U.S. on the ...
October 30, 2008October 30, 2008 - Abbott this week received a 2008 Chicago Innovation Award for its XIENCE V Everolimus Eluting ...
October 29, 2008October 21, 2008 - MIV Therapeutics Inc., a developer of coatings and drug-delivery systems for cardiovascular stents ...
October 20, 2008Feature | Dave Fornell
The stent wars continued at the Transcatheter Cardiovascular Therapeutics 2008 20th annual symposium last week with ...
October 20, 2008October 20, 2008 – At TCT last week Abbott announced two-year data from 30 patients in its ABSORB clinical trial ...
October 19, 2008October 17, 2008 - Boston Scientific Corp. announced results at TCT from an analysis of the HORIZONS-AMI trial showing a ...
October 16, 2008October 17, 2008 - Elixir Medical Corp. today announced results from three multicenter first-in-man studies of Novolimus ...
October 16, 2008October 15, 2008 - Boston Scientific Corp. announced estimated U.S. market shares for September for its two drug-eluting ...
October 14, 2008October 15, 2008 - The new name and branding for MEDRAD’s interventional products division was unveiled to the public at ...
October 14, 2008October 15, 2008 – At TCT 2008, Boston Scientific Corp. announced 12-month left main and three-vessel disease subset ...
October 14, 2008© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now